MA37748A1 - Composés d'azétidine et de pipéridine utiles comme inhibiteurs de pde10 - Google Patents
Composés d'azétidine et de pipéridine utiles comme inhibiteurs de pde10Info
- Publication number
- MA37748A1 MA37748A1 MA37748A MA37748A MA37748A1 MA 37748 A1 MA37748 A1 MA 37748A1 MA 37748 A MA37748 A MA 37748A MA 37748 A MA37748 A MA 37748A MA 37748 A1 MA37748 A1 MA 37748A1
- Authority
- MA
- Morocco
- Prior art keywords
- azetidine
- piperidine compounds
- compounds useful
- pde10 inhibitors
- pde10
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
L'invention concerne des composés d'azétidine et de pipéridine de formule (i) tels que définis dans le descriptif, des compositions les contenant, et des procédés de préparation de ces composés et leurs intermédiaires. L'invention concerne également des méthodes de traitement des maladies ou troubles cognitifs pouvant être traités par inhibition de pde10, tels que la maladie de huntington, la schizophrénie, les troubles bipolaires, les troubles obsessionnels-compulsifs et analogue.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261659911P | 2012-06-14 | 2012-06-14 | |
PCT/US2013/045768 WO2013188724A1 (fr) | 2012-06-14 | 2013-06-14 | Composés d'azétidine et de pipéridine utiles comme inhibiteurs de pde10 |
Publications (2)
Publication Number | Publication Date |
---|---|
MA37748A1 true MA37748A1 (fr) | 2016-11-30 |
MA37748B1 MA37748B1 (fr) | 2017-07-31 |
Family
ID=48692687
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA37748A MA37748B1 (fr) | 2012-06-14 | 2013-06-14 | Composés d'azétidine et de pipéridine utiles comme inhibiteurs de pde10 |
Country Status (25)
Country | Link |
---|---|
US (3) | US8691986B2 (fr) |
EP (1) | EP2864317A1 (fr) |
JP (1) | JP2015519402A (fr) |
KR (1) | KR20150023417A (fr) |
CN (1) | CN104619694A (fr) |
AP (1) | AP2014008136A0 (fr) |
AR (1) | AR091436A1 (fr) |
AU (1) | AU2013274153B2 (fr) |
BR (1) | BR112014031368A2 (fr) |
CA (1) | CA2875802A1 (fr) |
CL (1) | CL2014003391A1 (fr) |
CO (1) | CO7160011A2 (fr) |
CR (1) | CR20150012A (fr) |
EA (1) | EA201590014A1 (fr) |
HK (1) | HK1203935A1 (fr) |
IL (1) | IL235901A0 (fr) |
MA (1) | MA37748B1 (fr) |
MX (1) | MX2014014924A (fr) |
PE (1) | PE20150348A1 (fr) |
PH (1) | PH12014502780A1 (fr) |
SG (1) | SG11201408168UA (fr) |
TN (1) | TN2014000510A1 (fr) |
TW (1) | TWI508959B (fr) |
UY (1) | UY34858A (fr) |
WO (1) | WO2013188724A1 (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG185515A1 (en) | 2010-05-13 | 2012-12-28 | Amgen Inc | Nitrogen heterocyclic compounds useful as pde10 inhibitors |
UY34858A (es) * | 2012-06-14 | 2013-11-29 | Amgen Inc | Compuestos de azetidina y piperidina útiles como inhibidores de pde10 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4107288A (en) | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
PT72878B (en) | 1980-04-24 | 1983-03-29 | Merck & Co Inc | Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents |
US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
US8952037B2 (en) | 2010-05-13 | 2015-02-10 | Amgen Inc. | Heteroaryloxycarbocyclyl compounds as PDE10 inhibitors |
US8946230B2 (en) * | 2010-05-13 | 2015-02-03 | Amgen Inc. | Aryl- and heteroaryl- nitrogen-heterocyclic compounds as PDE10 inhibitors |
MX2012013127A (es) * | 2010-05-13 | 2012-11-30 | Amgen Inc | Compuestos heteroariloxiheterociclilo como inhibidores pde10. |
SG185515A1 (en) * | 2010-05-13 | 2012-12-28 | Amgen Inc | Nitrogen heterocyclic compounds useful as pde10 inhibitors |
UY34858A (es) * | 2012-06-14 | 2013-11-29 | Amgen Inc | Compuestos de azetidina y piperidina útiles como inhibidores de pde10 |
-
2013
- 2013-06-13 UY UY0001034858A patent/UY34858A/es not_active Application Discontinuation
- 2013-06-13 AR ARP130102085 patent/AR091436A1/es unknown
- 2013-06-14 EP EP13731237.7A patent/EP2864317A1/fr not_active Withdrawn
- 2013-06-14 MA MA37748A patent/MA37748B1/fr unknown
- 2013-06-14 AP AP2014008136A patent/AP2014008136A0/xx unknown
- 2013-06-14 TW TW102121229A patent/TWI508959B/zh not_active IP Right Cessation
- 2013-06-14 EA EA201590014A patent/EA201590014A1/ru unknown
- 2013-06-14 PE PE2014002438A patent/PE20150348A1/es not_active Application Discontinuation
- 2013-06-14 CA CA2875802A patent/CA2875802A1/fr not_active Abandoned
- 2013-06-14 KR KR1020147035700A patent/KR20150023417A/ko not_active Application Discontinuation
- 2013-06-14 JP JP2015517445A patent/JP2015519402A/ja active Pending
- 2013-06-14 SG SG11201408168UA patent/SG11201408168UA/en unknown
- 2013-06-14 AU AU2013274153A patent/AU2013274153B2/en not_active Expired - Fee Related
- 2013-06-14 BR BR112014031368A patent/BR112014031368A2/pt not_active IP Right Cessation
- 2013-06-14 CN CN201380031076.4A patent/CN104619694A/zh active Pending
- 2013-06-14 US US13/917,699 patent/US8691986B2/en active Active
- 2013-06-14 WO PCT/US2013/045768 patent/WO2013188724A1/fr active Application Filing
- 2013-06-14 MX MX2014014924A patent/MX2014014924A/es unknown
-
2014
- 2014-01-31 US US14/170,146 patent/US9303028B2/en active Active
- 2014-11-25 IL IL235901A patent/IL235901A0/en not_active IP Right Cessation
- 2014-12-04 TN TN2014000510A patent/TN2014000510A1/fr unknown
- 2014-12-11 PH PH12014502780A patent/PH12014502780A1/en unknown
- 2014-12-12 CL CL2014003391A patent/CL2014003391A1/es unknown
-
2015
- 2015-01-08 CO CO15003862A patent/CO7160011A2/es unknown
- 2015-01-13 CR CR20150012A patent/CR20150012A/es unknown
- 2015-05-07 HK HK15104351.8A patent/HK1203935A1/xx unknown
-
2016
- 2016-03-01 US US15/058,023 patent/US9493459B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US9493459B2 (en) | 2016-11-15 |
SG11201408168UA (en) | 2015-01-29 |
JP2015519402A (ja) | 2015-07-09 |
TN2014000510A1 (en) | 2016-03-30 |
PE20150348A1 (es) | 2015-03-04 |
AU2013274153A1 (en) | 2014-12-18 |
MA37748B1 (fr) | 2017-07-31 |
UY34858A (es) | 2013-11-29 |
US20130338138A1 (en) | 2013-12-19 |
US8691986B2 (en) | 2014-04-08 |
WO2013188724A1 (fr) | 2013-12-19 |
US20160176874A1 (en) | 2016-06-23 |
CR20150012A (es) | 2015-02-11 |
CO7160011A2 (es) | 2015-01-15 |
IL235901A0 (en) | 2015-09-24 |
TWI508959B (zh) | 2015-11-21 |
AR091436A1 (es) | 2015-02-04 |
MX2014014924A (es) | 2015-03-09 |
CA2875802A1 (fr) | 2013-12-19 |
TW201412729A (zh) | 2014-04-01 |
EA201590014A1 (ru) | 2015-04-30 |
KR20150023417A (ko) | 2015-03-05 |
US9303028B2 (en) | 2016-04-05 |
CN104619694A (zh) | 2015-05-13 |
EP2864317A1 (fr) | 2015-04-29 |
AU2013274153B2 (en) | 2016-05-19 |
PH12014502780A1 (en) | 2015-02-02 |
BR112014031368A2 (pt) | 2017-06-27 |
HK1203935A1 (en) | 2015-11-06 |
US20140148435A1 (en) | 2014-05-29 |
AP2014008136A0 (en) | 2014-12-31 |
CL2014003391A1 (es) | 2015-07-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA34300B1 (fr) | Composés azotés hétérocycliques convenant comme inhibiteurs de la pde10 | |
MA47079B1 (fr) | Composés amino-triazolopyidines et leur utilisation pour traiter le cancer | |
MA33119B1 (fr) | Derives de benzofuranyle utilises comme inhibiteurs de la glucokinase | |
MA40290A1 (fr) | Agents immunorégulateurs | |
MA40955B1 (fr) | 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1 | |
EA201591614A1 (ru) | Соединения 1,3-оксазин-2-амина, конденсированные с перфторированным циклопропилом, в качестве ингибиторов бета-секретазы и способы их применения | |
MA32891B1 (fr) | Derives de pyridine et de pyrimidine comme inhibiteurs de phosphodiesterase 10 | |
MA32035B1 (fr) | Composes tricycliques servant de modulateurs de synthese de tnf-alpha et d'inhibiteurs de pde4 | |
MA38483A1 (fr) | Inhibiteurs de l'ido | |
MA39225A1 (fr) | 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tétrahydropyridines utilisées en tant qu'inhibiteurs de bace1 dans le traitement de la maladie d'alzheimer | |
MA38090A1 (fr) | Dérivés de 5-fluoro-n-(pyridin -2-yl)pyridin-2-amines contenant un groupe sulfoximine | |
MX2008010671A (es) | Derivados de cinolina como inhibidores de fosfodiesterasa 10. | |
MA38227B1 (fr) | Nouveaux composés bicycliques et leur utilisation en tant qu'agents antibactériens et inhibiteurs de ß-lactamase | |
MA32466B1 (fr) | Derives de triazole utiles pour le traitement de maladies | |
MA37762B1 (fr) | Composés n-aryltriazole utilisés comme antagonistes de lpar | |
MA37764A1 (fr) | Composés n-alkyltriazole utilisés comme antagonistes de lpar | |
MA37439A1 (fr) | Inhibiteurs de dgat1 à ponts éthers cycliques pour le traitement de troubles medies par l'acyle coa-diacylglycerol transferase 1 (dgat1). | |
MA35342B1 (fr) | Composés de-pipéridinyle utiles comme inhibiteurs de la tankyrase | |
MA34896B1 (fr) | Inhibiteurs du virus de l'hepatite c | |
MA50391B1 (fr) | Composés d' imidazo[4,5-b]pyridine et compositions pharmaceutiques les contenant destinés à traiter les troubles inflammatoires | |
MA35444B1 (fr) | Ligands du récepteur ep1 | |
MA38091A2 (fr) | Dérivés n-(pyridin-2-yl)pyrimidin-4-amines contenant un groupe sulfoximine | |
MA46229B1 (fr) | Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2 | |
MA39253A1 (fr) | Composés hétéroaryle bicycliques substitués utilisés comme agonistes de rxr | |
MA37748A1 (fr) | Composés d'azétidine et de pipéridine utiles comme inhibiteurs de pde10 |